Comparative Pharmacology
Head-to-head clinical analysis: NASACORT HFA versus QVAR 40.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NASACORT HFA versus QVAR 40.
NASACORT HFA vs QVAR 40
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators (e.g., cytokines, prostaglandins) and reducing nasal inflammation.
Beclomethasone dipropionate is a corticosteroid with potent anti-inflammatory activity. It binds to glucocorticoid receptors, leading to modulation of gene expression and inhibition of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. It reduces airway hyperresponsiveness and inflammation.
55 mcg (1 spray) per nostril once daily; may increase to 110 mcg (2 sprays) per nostril once daily if needed. Maximum 440 mcg/day total.
40-160 mcg inhaled twice daily for asthma maintenance; maximum 320 mcg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 3.5 hours following intranasal administration, reflecting slow systemic absorption and prolonged local retention.
Terminal elimination half-life is approximately 2.9 hours in adults after inhalation, reflecting rapid clearance from plasma.
Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites and parent drug)
Primarily hepatic metabolism via CYP3A4, with inactive metabolites excreted in feces (approximately 60-70%) and urine (30-40%). Less than 10% excreted unchanged.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid